Financials in USD. Standardized financial statements.
A compact view of how Rapid Dose Therapeutics Corp. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.09M | $1.02M | $718,298 | $1.75M | $755,201 | $101,498 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +104.4% | +42.0% | -59.0% | +132.0% | +644.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $905,117 | $457,015 | $345,894 | $407,119 | $55,351 | $64,161 | $156,277 | $0 | $0 | $0 |
| Gross Profit? | $1.18M | $563,409 | $372,404 | $1.34M | $699,850 | $37,337 | -$156,000 | $0 | $0 | $0 |
| Gross Margin? | +56.6% | +55.2% | +51.8% | +76.8% | +92.7% | +36.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | -$4.22M | $4.30M | $4.18M | $5.78M | $2.48M | $7.65M | $11.48M | $50,079 | $47,097 | $51,744 |
| Operating Income? | $5.40M | -$3.74M | -$3.81M | -$4.43M | -$1.78M | -$7.61M | -$11.48M | -$50,079 | -$47,097 | -$51,744 |
| EBITDA? | -$3.93M | -$3.02M | -$2.92M | -$7.59M | -$987,000 | -$7.37M | -$11.32M | -$50,079 | -$47,097 | -$51,744 |
| Income Before Tax | -$5.40M | -$4.31M | -$3.81M | -$8.49M | -$1.80M | -$7.96M | -$11.40M | -$50,079 | -$47,097 | -$51,744 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$5.40M | -$4.31M | -$3.81M | -$8.49M | -$1.80M | -$7.96M | -$11.40M | -$50,079 | -$47,097 | -$51,744 |
| EPS? | $-0.04 | $-0.04 | $-0.04 | $-0.08 | $-0.03 | $-0.10 | $-0.18 | $-0.05 | $-0.06 | $-0.11 |
| Diluted EPS? | $-0.04 | $-0.04 | $-0.04 | $-0.08 | $-0.03 | $-0.10 | $-0.18 | $-0.05 | $-0.06 | $-0.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality